Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery

Liver Cancer Clinical Trial

Official title:

Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01313377
• Other study ID #: CDR0000696193
• Secondary ID: FRE-FNCLCC-ACCOR
• Status: Completed
• Phase: Phase 3
• First received: March 10, 2011
• Last updated: January 24, 2017
• Start date: July 2009
• Est. completion date: June 2016

Study information

• Verified date: January 2017
• Source: UNICANCER
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Observation is watching a patient's condition but not giving treatment until symptoms appear. It is not yet known whether giving gemcitabine hydrochloride together with oxaliplatin is more effective than observation in treating patients with biliary tract cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.

Description:

OBJECTIVES:

Primary

• Compare disease-free survival (DFS) of patients with resected biliary tract cancer treated with adjuvant gemcitabine hydrochloride and oxaliplatin versus clinical observation.

• Compare quality of life of these patients.

Secondary

• Compare overall survival of these patients.

• Determine the toxicity of the chemotherapy in these patients.

• Explore prognostic factors for DFS including resection result (R0 vs R1), location of primary tumor (intrahepatic vs extrahepatic vs gallbladder), evolution of CA19-9, and lymph node involvement (N0 vs N+ and Nx). (Exploratory)

• Study pathological factors in surgical specimens to identify main characteristics and phenotypic clinicoanatomical biliary tract cancers before therapy. (Exploratory)

• Identify nontumor-associated liver injury and factors that may facilitate the emergence of biliary tract cancers. (Exploratory)

• Identify signaling pathways that may predict response to therapy. (Exploratory)

• Determine the molecular characteristics to differentiate tumors according to their position in the biliary tract (extrahepatic bile duct, intrahepatic cholangiocarcinoma site [hilar], and peripheral cholangiocarcinoma vesicle site). (Exploratory)

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 14 days for 12 courses.

• Arm II: Patients undergo clinical observation only every 4 weeks for 5 months. Quality of life is assessed at baseline, at 3 and 6 months, and then at all follow-up visits.

After completion of study therapy, patients are followed up at 6 months, every 3 months for 2 years, and then every 6 months for 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 190
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically proven adenocarcinoma of the intrahepatic bile ducts, gallbladder, or extrahepatic bile ducts

• Mixed forms of hepatocholangiocarcinomas included provided the cholangiocarcinoma is predominant

• Underwent surgical resection of the disease (R0 or R1) at least 4 weeks but no more than 13 weeks ago

• Nonmetastatic disease as assessed by abdominal MRI and chest x-ray

• No cancer of the pancreas or duodenum invading the bile duct and ampulla of Vater

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Hemoglobin = 10 g/dL (transfusion allowed)

• ANC = 1,500/mm³

• Platelet count = 75,000/mm³

• Creatinine clearance > 40 mL/min

• Prothrombin time > 60% OR INR < 1.5 (without anticoagulant therapy)

• Transaminases = 5 times upper limit of normal (ULN)

• Alkaline phosphatase = 2.5 times ULN

• Conjugated bilirubin = 35 µmol/L (after biliary drainage, if necessary)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No contraindications to oxaliplatin and gemcitabine hydrochloride therapy

• Prior invasive cancer allowed provided it has been in complete remission for = 5 years

• No other concurrent invasive cancer except adequately treated carcinoma in situ of the cervix or basal cell carcinoma

• No other severe, unresolved disease

• No mental illness

• No HIV positivity

• No grade 1 angina or symptomatic angina = grade 2

• No sensitive peripheral neuropathy

• No uncontrolled diabetes

• No inability to undergo medical tests due to geographical, social, or psychological reasons

• No prisoners or patients under guardianship

• No Child B or C cirrhosis

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior neoadjuvant chemotherapy or radiotherapy

• No prior organ transplantation

• No concurrent participation in another clinical trial of an experimental agent

Related Conditions & MeSH terms

• Bile Duct Neoplasms
• Biliary Tract Neoplasms
• Extrahepatic Bile Duct Cancer
• Gallbladder Cancer
• Gallbladder Neoplasms
• Liver Cancer
• Liver Neoplasms

Intervention

Drug:
• gemcitabine hydrochloride

• oxaliplatin

Other:
• clinical observation

Procedure:
• adjuvant therapy

• quality-of-life assessment

Locations

Country	Name	City	State
France	CHU - Hôpital Nord	Amiens
France	Centre Paul Papin	Angers
France	Institut Sainte Catherine	Avignon
France	Centre hospitalier de la Côte Basque	Bayonne
France	Hôpital Jean Minjoz	Besancon
France	Hôpital Avicenne	Bobigny
France	CHU Brest - Hôpital Morvan	Brest
France	CHU Côte de Nacre	Caen
France	CHU Estaing	Clermont Ferrand
France	Hôpital Beaujon	Clichy
France	Hôpital Henri Mondor	Créteil
France	Hôpital Bocage	Dijon
France	CHD Vendée	La Roche Sur Yon
France	Centre Léon Bérard	Lyon
France	Hôpital Edouard Herriot	Lyon
France	Hôpital Privé Jean Mermoz	Lyon
France	CHU Timone Adulte	Marseille
France	Hôpital Nord	Marseille
France	Hôpital Saint Joseph	Marseille
France	Institut Paoli Calmettes	Marseille
France	Centre Hospitalier Saint Eloi	Montpellier
France	Centre René Gauducheau	Nantes
France	Hôpital La Source	Orléans
France	CHU Saint Louis	Paris
France	Hôpital de la Pitié Salpétrière	Paris
France	Hôpital Européen Georges Pompidou	Paris
France	Hôpital Saint Antoine	Paris
France	Institut Mutualiste Montsouris	Paris
France	CHU de Poitiers	Poitiers
France	Centre Eugene Marquis	Rennes
France	CHU de Rouen - Hôpital Ch. Nicolle	Rouen
France	CHU Sainte-Etienne - Hopital Nord	Sainte-Etienne
France	Centre Paul Strauss	Strasbourg
France	Hôpital de Hautepierre / Hôpital Civil	Strasbourg
France	Hôpital Trousseau	Tours
France	CHU Brabois	Vandouevre Les Nancy
France	Institut Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		up to 3 years
Primary	Quality of life		up to 3 years
Secondary	Overall survival		up to 3 years
Secondary	Toxicity of adjuvant chemotherapy		up to 3 years